ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Plasmapheresis"

  • 2018 American Transplant Congress

    Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute

    H. Harada, Y. Wada, A. Mitsuke, T. Hirose, N. Fukuzawa, T. Seki.

    Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.

    INTRODUCTION: An ABO incompatible kidney transplant (ABOiKT) requires desensitization (DS). The ways of DS have been changed chronologically and the outcome could have been subsequently…
  • 2018 American Transplant Congress

    Long-Term Success of Treatment for Cardiac Transplant AMR May Depend Upon Suppressing Class II Donor Specific Antibodies

    J. Hofmann,1 D. Weisshaar,2 D. Kiprov.3

    1Dept of Medicine, California Pacific Medical Center, San Francisco, CA; 2Dept of Medicine, Kaiser Permanente, Santa Clara, CA.

    Antibody mediated rejection (AMR) in cardiac transplant (tspt) patients (pts) is primarily mediated by donor specific antibodies (DSAs) and associated with reduced long-term graft survival.…
  • 2018 American Transplant Congress

    Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients

    E. Kincaide,1,2,3 K. Hitchman,1,3 R. Hall,1,2,3 I. Yamaguchi,3 B. Crowther.1,2,3

    1University Health System, San Antonio, TX; 2College of Pharmacy, Pharmacotherapy Division, The University of Texas at Austin, Austin, TX; 3UT Health San Antonio, San Antonio, TX.

    Purpose: Characterize class I and class II donor specific antibodies (DSA) response to acute antibody mediated rejection (AMR) treatment in pediatric kidney transplant recipients (KTR).Methods:…
  • 2018 American Transplant Congress

    Recurrence of Focal Segmental Glomerulosclerosis (FSGS) and Response to Prolonged Plasmapheresis Therapy: A Single Center Pediatric Experience

    A. Bobrowski, D. Matossian.

    Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL.

    FSGS is the most common glomerular cause of ESKD in pediatric patients. The risk of recurrence after kidney transplant (KT) is 30-60%, and half of…
  • 2018 American Transplant Congress

    Efficacy and Safety of Acute Antibody Rejection Treatment in Pediatric Kidney Transplant Recipients

    E. Kincaide,1,2,3 K. Hitchman,1,3 R. Hall,1,2,3 I. Yamaguchi,3 B. Crowther.1,2,3

    1University Health System, San Antonio, TX; 2College of Pharmacy, Pharmacotherapy Division, The University of Texas at Austin, San Antonio, TX; 3UT Health San Antonio, San Antonio, TX.

    Purpose: Evaluate the efficacy and safety of acute antibody mediated rejection (AMR) treatment modalities in pediatric kidney transplant recipients (KTR).Methods: A single-center retrospective chart review…
  • 2018 American Transplant Congress

    Preemptive Plasma Therapy and Eculizumab (ECU) Rescue for Atypical Hemolytic Uremic Syndrome (aHUS) Relapse Following Kidney Transplantation (KTX)

    C. Aigner,1,2 G. Böhmig,1 F. Eskandary,1 M. Gaggl,1 R. Kain,2 R. Sunder-Plassmann,3 Z. Prohaszka,4 A. Schmidt,1 G. Sunder-Plassmann.1

    1Division of Nephrology and Dialysis, Medical University Vienna, Vienna, Austria; 2Clinical Institute of Pathology, Medical University Vienna, Vienna, Austria; 3Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; 43rd Department of Medicine, Semmelweis University, Budapest, Hungary.

    Introduction: KTX in aHUS patients is associated with a high rate of relapse and graft loss. Here, we report on seven aHUS cases with end-stage…
  • 2018 American Transplant Congress

    Treatment Outcomes of FSGS Recurrence

    J. Mansur,1 D. Chang,2 G. Medeiros,1 M. Cristelli,1 L. Viana,1 S. Stopa,1 C. Felipe,1 G. Kirsztajn,1 H. Tedesco-Silva.1

    1Hospital do Rim, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; 2Hospital Nacional Cayetano Heredia, Universidad Peruana Cayetano Heredia, Lima, Peru.

    Background: Recurrence of FSGS (focal segmental glomerulosclerosis) after kidney transplant occurs in 30% of adults and up to 80% of children and has impact on…
  • 2017 American Transplant Congress

    Successful Launch of an ABO-Incompatible Kidney Transplantation Program to Overcome the Shortage of Compatible Living Donors: Experience at a Single Center.

    S. Song,1 J. Lee,1 J. Lee,1 S.-K. Kwon,1 B. Kim,2,3 J. Lee,1 Y. Kim,1,3 M. Kim,1,3 S. Kim,1,3 K. Huh.1,3

    1Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea; 2Nephrology, Yonsei University Health System, Seoul, Republic of Korea; 3The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea

    Introduction:ABO-incompatible (ABOi) kidney transplantation (KT) is being increasingly performed to overcome donor shortages. However, debate persists regarding the post-transplant outcomes of ABOi KT versus that…
  • 2017 American Transplant Congress

    Outcome of ABO-Incompatible Kidney Transplantation After Stratified Desensitization.

    K. Nanmoku, A. Kurosawa, T. Kubo, T. Shinzato, T. Shimizu, T. Kimura, T. Yagisawa.

    Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan

    Background. Plasmapheresis for antibody removal and rituximab for antibody production suppression are performed for desensitization against ABO-incompatible kidney transplantation. We evaluated clinical outcome for optimizing…
  • 2017 American Transplant Congress

    The Inhibitory Effect of Plasma on T Cell Activation: Possible Role of Plasma Exchange in Anti Rejection Therapy.

    A. Assounga,1,2 S. Omarjee.1

    1Dept Nephrology, University of KwaZulu-Natal, Durban, South Africa; 2Inkosi Albert Luthuli Central Hospital, Durban, South Africa

    Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented.Aim: To compare…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences